Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03386474 (CRTH258A2301E1) Neovascular age-related macular degeneration (nAMD) Phase 3 150 Number of treatment-emergent adverse events Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study Target Patients Read-out Milesstone(s) 2018 (actual) Publication Planned publication of the attributes of brolucizumab and durability in H1-2021 NCT03481634 KESTREL (CRTH258B2301) Diabetic eye disease Phase 3 534 Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 3 mg/50 μL Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2mg/50 uL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q4-2020 (actual); Final: H2-2021 Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 119 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation